EZH2 and metastatic malignant neoplasm in the lymph nodes: When adjusting for potential confounding factors, including age, tumor differentiation, tumor size, lymph node metastasis, and muscle invasion, the multivariate analysis identified the muscle invasion (HR = 3.25, 95%Cl: 1.48–5.42, p = 0.021), tumor size (HR = 2.24, 95%Cl: 1.52–3.42, p = 0.004), and EZH2 levels (HR = 3.07, 95%Cl: 2.11–5.09, p = 0.006) as independent risk factors for overall survival rates (Table 3).